Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.

Suzuki O, Mizukami K, Etori M, Sogawa Y, Takagi N, Tsuchida H, Morimoto K, Goto T, Yoshino T, Mikkaichi T, Hirahara K, Nakamura S, Maeda H.

J Pharmacol Sci. 2013;123(3):219-26. Epub 2013 Oct 22.

2.

The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.

Konrad FM, Bury A, Schick MA, Ngamsri KC, Reutershan J.

PLoS One. 2015 Apr 24;10(4):e0121725. doi: 10.1371/journal.pone.0121725. eCollection 2015.

3.

Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R.

Pulm Pharmacol Ther. 2006;19(5):343-52. Epub 2005 Oct 28.

PMID:
16257550
4.

The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor.

Suzuki O, Goto T, Yoshino T, Nakamura S, Maeda H.

Acta Pharm. 2015 Jun;65(2):191-7. doi: 10.1515/acph-2015-0016.

PMID:
26011935
5.

Roflumilast (Daliresp) for COPD.

[No authors listed]

Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60. No abstract available.

PMID:
21778965
6.

Roflumilast for severe COPD?

[No authors listed]

Drug Ther Bull. 2011 Apr;49(4):45-8; quiz iii-iv. doi: 10.1136/dtb.2011.02.0025. Review.

PMID:
21467576
7.

Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.

Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, Shimizu Y.

Int Immunopharmacol. 2012 Jan;12(1):59-63. doi: 10.1016/j.intimp.2011.10.011. Epub 2011 Oct 29.

PMID:
22041526
8.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.

Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7. Review.

PMID:
20381629
9.

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.

Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A.

PLoS One. 2013;8(2):e56867. doi: 10.1371/journal.pone.0056867. Epub 2013 Feb 28.

10.

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.

Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W.

J Clin Pharmacol. 2002 Mar;42(3):297-303.

PMID:
11865966
11.

Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.

Chapman RW, House A, Jones H, Richard J, Celly C, Prelusky D, Ting P, Hunter JC, Lamca J, Phillips JE.

Eur J Pharmacol. 2007 Oct 1;571(2-3):215-21. Epub 2007 Jun 16.

PMID:
17610865
12.

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.

J Pharmacol Exp Ther. 2009 Sep;330(3):922-31. doi: 10.1124/jpet.109.152454. Epub 2009 Jun 4.

13.

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, Shimizu Y.

Int Immunopharmacol. 2011 Jun;11(6):732-9. doi: 10.1016/j.intimp.2011.01.023. Epub 2011 Feb 23.

PMID:
21315169
14.

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R.

J Pharmacol Exp Ther. 2001 Apr;297(1):280-90.

15.

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Rabe KF.

Br J Pharmacol. 2011 May;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x. Review.

16.

[Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].

Shmelev EI, Shmeleva NM.

Ter Arkh. 2012;84(6):73-6. Russian.

PMID:
22997924
17.

Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.

Rogliani P, Calzetta L, Cazzola M, Matera MG.

Expert Opin Drug Saf. 2016 Aug;15(8):1133-46. doi: 10.1080/14740338.2016.1199683. Epub 2016 Jun 20. Review.

PMID:
27279341
18.

Roflumilast added to triple therapy in patients with severe COPD: a real life study.

Muñoz-Esquerre M, Diez-Ferrer M, Montón C, Pomares X, López-Sánchez M, Huertas D, Manresa F, Dorca J, Santos S.

Pulm Pharmacol Ther. 2015 Feb;30:16-21. doi: 10.1016/j.pupt.2014.10.002. Epub 2014 Oct 30.

PMID:
25445930
19.

New therapeutic options in the management of COPD - focus on roflumilast.

Antoniu SA.

Int J Chron Obstruct Pulmon Dis. 2011;6:147-55. doi: 10.2147/COPD.S7336. Epub 2011 Feb 17. Review.

20.

GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.

Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman J, Ward P, Ranshaw LE, Knowles RG.

J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. doi: 10.1124/jpet.110.173690. Epub 2011 Jan 4.

Supplemental Content

Support Center